The company's molecular and cytogenetic diagnostic platform provides a comprehensive menu of assay services for diagnosing and guiding precise therapeutic treatments for patients, advancing biomarker research, accelerating diagnoses, and improving personalized treatment options for patients battling cancer and other complex diseases. Empire's mission is to enable personalized medicine through the development and implementation of genetic assays, with the goal of faster and more effective drug development, lower healthcare costs, and better clinical outcomes. The company is uniquely positioned to bring this innovative service to the medical community through its highly qualified team, certified facilities, and strategic partnerships with leaders in the global research community.